PhilipEdwardLammersMD

Chief of Medical Oncology, Medical Director of Clinical Oncology Research, Medical Oncologist

Overview of Dr. Lammers

Dr. Philip Lammers is an oncologist in Memphis, TN and is affiliated with Baptist Memorial Hospital-Tipton. He received his medical degree from Indiana University School of Medicine and has been in practice 11 years. He is one of 18 doctors at Baptist Memorial Hospital-Tipton who specialize in Oncology. He has more than 30 publications and over 500 citings.

Office
80 Humphreys Center
Suite 330
Memphis, TN 38120
Book by Phone+1(901) 657-4910

Education & Training

Vanderbilt University Medical CenterFellowship, Hematology and Medical Oncology, 2009 - 2012
Washington University/B-JH/SLCH ConsortiumResidency, Internal Medicine, 2006 - 2009
Indiana University School of MedicineClass of 2006

Certifications & Licensure

MS State Medical License 2019 - 2025
TN State Medical License 2009 - 2025
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Clinical Trials

Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer Start of enrollment: 2015 Jul 26
Active, not recruiting
Phase 3
Lung-MAP: Taselisib as Therapy in Treating Patients With Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches Start of enrollment: 2014 Nov 01
Completed
Phase 2
Lung-MAP: Palbociclib as Second-Line Therapy in Treating Cell Cycle Gene Alteration Positive Patients With Recurrent Stage IV Squamous Cell Lung Cancer Start of enrollment: 2014 Sep 01
Completed
Phase 2, Phase 3
Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers Start of enrollment: 2015 Dec 29
Active, not recruiting
Phase 3
Join now to see all

Publications & Presentations

PubMed

Practical management of adverse events in patients receiving tarlatamab, a delta-like ligand 3-targeted bispecific T-cell engager immunotherapy, for previously treated...
Jacob M Sands, Stéphane Champiat, Horst-Dieter Hummel, Kelly G Paulson, Hossein Borghaei
Cancer. 2025-02-01
Barriers to Lung Cancer Screening in a Multi-Disciplinary Thoracic Oncology Program Cohort: Effects of an Incidental Pulmonary Nodule Program.
Wei Liao, Meredith A Ray, Anita Patel, Jessica Roma, Hope Marshall
Journal of Thoracic Oncology. 2025-01-30
3 citations
A Phase 1/2 Study to Evaluate the Safety and Activity of Nivolumab in Combination With Vorolanib, a Vascular Endothelial Growth Factor Tyrosine Kinase Inhibitor, in Pa...
Kathryn E Beckermann, Christine M Bestvina, Badi El Osta, Rachel E Sanborn, Hossein Borghaei
JTO Clinical and Research Reports. 2024-02-01

Press Mentions

Memphis People in Business: March 25, 2021March 25th, 2021
FDA Approves Herceptin Biosimilar Ontruzant for HER2-Positive Breast CancerJuly 24th, 2019
Cancer Disparities Grant with Meharry, TSU Gains RenewalOctober 20th, 2016
Join now to see all